Polyclonal Antibody to Hypoxanthine Phosphoribosyltransferase 1 (HPRT1) Homo sapiens (Human) Polyclonal antibody

HGPRT; HGPRTase; HPRT; Lesch-Nyhan Syndrome; Hypoxanthine-guanine phosphoribosyltransferase

  • Polyclonal Antibody to Hypoxanthine Phosphoribosyltransferase 1 (HPRT1) Packages (Simulation)
  • Polyclonal Antibody to Hypoxanthine Phosphoribosyltransferase 1 (HPRT1) Packages (Simulation)
  • Polyclonal Antibody to Hypoxanthine Phosphoribosyltransferase 1 (HPRT1) Figure. DAB staining on IHC-P; Samples: Human Lung Cancer Tissue.
  • Polyclonal Antibody to Hypoxanthine Phosphoribosyltransferase 1 (HPRT1) Figure. DAB staining on IHC-P;
    Samples: Human Liver Tissue.
  • Polyclonal Antibody to Hypoxanthine Phosphoribosyltransferase 1 (HPRT1) Figure. DAB staining on IHC-P;
    Samples: Human Liver Cancer Tissue.
  • Polyclonal Antibody to Hypoxanthine Phosphoribosyltransferase 1 (HPRT1) Figure. DAB staining on IHC-P;
    Samples: Human Glioma Tissue.
  • PAA717Hu01.jpg Figure. Western Blot; Sample: Recombinant HPRT1, Human.
  • Polyclonal Antibody to Hypoxanthine Phosphoribosyltransferase 1 (HPRT1) Figure. Western Blot; Sample: Lane1: Rat Liver Tissue; Lane2: Rat Brain Tissue; Lane3: Human Hela Cells; Lane4: Human HepG2 Cells; Lane5: Human A549 Cells.
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

SPECIFITY

The antibody is a rabbit polyclonal antibody raised against HPRT1. It has been selected for its ability to recognize HPRT1 in immunohistochemical staining and western blotting.

USAGE

Western blotting: 0.5-5µg/mL
Immunohistochemistry: 5-20µg/mL
Immunocytochemistry: 5-20µg/mL
Optimal working dilutions must be determined by end user.

STORAGE

Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for one year without detectable loss of activity. Avoid repeated freeze-thaw cycles.

STABILITY

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Reference

  • J Crohns Colitis.Response to infliximab therapy in ulcerative colitis is associated with decreased monocyte activation, reduced CCL2 expression and downregulation of Tenascin C.Pubmed:25518051
  • J CrohnsResponse to infliximab therapy in ulcerative colitis is associated with decreased monocyte activation, reduced CCL2 expression and downregulation of tenascin CPubMed: 25518051